Transcriptome-wide mapping reveals an RNA-dependent mechanism of platinum cancer drugs.

ABSTRACT: Small molecules developed to target proteins or DNA may also bind RNA, but the extent and biological significance of such interactions among oncology drugs remain poorly defined. Here, we systematically profiled RNA interactions of a cohort of clinically approved anticancer agents and uncovered widespread RNA off-targeting. Cisplatin, a frontline chemotherapeutic agent for solid tumors, has emerged as a prominent RNA-binding drug. While the primary mechanism of action of cisplatin has been attributed to DNA damage-induced apoptosis, it has also been shown to bind RNA molecules. However, the extent of RNA binding in cancer cells and its functional relevance in platinum-based chemotherapy remained unknown. To map specific RNA targets of cisplatin in vivo, we developed PlatRNA-seq, a c

SUBMITTER: Krishnaraj A 

PROVIDER: S-EPMC12776116 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature